Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.40 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3516061 | 0.96 | PDE4B (0.47) | LMNAPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3513309 | 0.91 | PIK3CA (0.50) | LMNAPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL12986447 | 0.88 | TNF (0.42) | PIK3CAPIK3CDPIK3CBPIK3CGPDE4B | |
| SCHEMBL3513489 | 0.88 | IKBKB (0.48) | LMNAPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3514650 | 0.87 | CAMK2D (0.48) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL3513040 | 0.87 | PDE4B (0.52) | LMNAPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL3514542 | 0.84 | IKBKB (0.53) | PIK3CAMTORALDH1A1GAAPDE4B | |
| SCHEMBL3514034 | 0.84 | PIK3CA (0.41) | PIK3CAPIK3CDPIK3CBPIK3CGKDM4E | |
| SCHEMBL3516403 | 0.83 | MKNK1 (0.51) | PIK3CAKDM4EALDH1A1GLAGAA | |
| SCHEMBL3515987 | 0.83 | CAMK2D (0.52) | PIK3CATNFCAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | claimed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | LMNA 4734/4885PIK3CA 10/4885PIK3CD 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.